If a platform refuses to reveal its strategy's core logic, citing "trade secrets," is that reasonable?
Some degree of confidentiality is reasonable — fully disclosing the details of a strategy's logic could let others replicate it or even front-run the same market opportunity, which is a normal business consideration. But "keeping the specific parameters and code details confidential" is a different thing from "refusing to explain what pattern the strategy is capturing at all." A responsible platform can usually state the general type of logic in one sentence without leaking its actual code — for example, "this is a cross-chain interest rate arbitrage strategy" — while withholding the precise numerical trigger thresholds.
If a platform won't even reveal this high-level category of logic and only offers vague terms like "AI-powered smart decisions," that level of secrecy goes beyond a reasonable trade-secret boundary — it more likely suggests the strategy itself lacks clear logic, or the team doesn't want users able to judge its plausibility for themselves.
If out-of-sample performance is only slightly worse than in-sample, is that normal or does it still count as overfitting?
That's normal and doesn't indicate overfitting. Out-of-sample performance being somewhat weaker than in-sample is nearly inevitable — after all, in-sample data is what the strategy has "seen" and been tuned against, while out-of-sample data is completely unfamiliar. Some degree of gap is a reasonable statistical phenomenon and nothing to be overly alarmed about. What actually warrants concern is the size of that gap, not whether a gap exists at all.
Concretely: if in-sample annualized return is 50% and out-of-sample is 35%, that kind of gap is usually still within a reasonable range; but if in-sample annualized return is 50% and out-of-sample flips straight into a loss or near-zero return, that kind of cliff-edge gap is a clear signal of overfitting. The key judgment is whether out-of-sample performance still maintains positive results of a similar magnitude — not whether it matches in-sample performance exactly.
How do you assess overfitting risk for a brand new DeFAI strategy that has no live track record yet?
A brand new strategy is indeed harder to judge using the "live vs. backtest" gap, but you can still work from the other two checks: whether the core logic can be simply explained, and whether the backtest itself was validated out-of-sample. Neither of these depends on live trading time, so they can be checked before the strategy even launches. Beyond that, it's worth checking whether the strategy's team has other products that have been live for a while — if the same team's past strategies commonly show a pattern of "impressive backtest, disappointing live performance," that's a track record worth factoring in.
For a completely new team and a completely new strategy with no history to reference at all, the most practical approach is to let it run for a while with an amount of capital you'd be entirely fine losing, accumulating real live data, rather than deciding your commitment size based on a single backtest report alone.
If I don't understand statistics or quantitative analysis at all, are these three checks too difficult for me?
None of these three methods require a statistics background — they just require a willingness to spend time looking things up and asking questions. The first check is simply asking "was this validated out-of-sample" — you don't need to calculate anything yourself; the second check is just judging "do I actually understand this explanation," something ordinary intuition can handle; the third check is just comparing a timeline for an obvious performance turning point — no precise statistical tools needed, just eyeballing the trend of a return curve.
The real barrier isn't statistical knowledge — it's whether you're willing to spend an extra five minutes asking these three questions before being convinced by an attractive number. Most people don't lose money because they can't understand statistics — they lose money because they never stopped to ask these questions at all.
Almost every DeFAI product's marketing page shows off a beautiful backtest return curve, but a good-looking curve doesn't mean the strategy actually works. Backtest overfitting is one of the easiest traps to fall for in this industry — a strategy developer doesn't need to be malicious; simply tuning parameters repeatedly against the same historical data is enough to produce a curve that looks perfect but doesn't hold up under scrutiny. This article breaks down three checks an ordinary user can try themselves, to help judge whether the backtest data in front of you is real skill or coincidence.
This is the most direct way to spot overfitting. A rigorous strategy validation process splits historical data into two segments: one used for tuning parameters (in-sample) and one entirely withheld from tuning, used only for final verification (out-of-sample). If a product only displays in-sample performance figures and never mentions out-of-sample results, it usually means either that step was never done, or it was done and the results weren't good enough to publish. Ask support or check the documentation directly: was this backtest validated out-of-sample? Not being able to answer, or dodging the question, is itself a signal.
A strategy that genuinely captures a market pattern usually has a core logic that can be explained simply — like "enter when the two sides of a liquidity pool diverge in price by a specific ratio." If a strategy's description is nothing more than vague language like "an AI model dynamically decides based on multiple indicators," with no concrete statement of what pattern it's actually capturing, that usually means the logic is so complex even the developer struggles to simplify it — and the more complex the logic and the more tunable parameters involved, the higher the overfitting risk tends to be.
Most legitimate products have a clear point in time marking "backtest ends, live trading begins." If you can find performance data around that point, the key thing to watch isn't the absolute return level, but whether there's a sudden performance cliff — from consistently positive returns during the backtest period to a sudden shift into consecutive losses or dramatically shrinking returns once live trading starts. This kind of cliff is usually the most direct evidence of overfitting, since the strategy is now facing entirely new data it was never "trained" on.
If a product can't provide out-of-sample validation data at all, can't clearly explain its logic, and hasn't been live long enough to reveal a trend, that doesn't necessarily mean the strategy is overfit — it means the information you currently have isn't enough to rule out that possibility. With insufficient information, the safer approach is to actually test with a small amount of capital for a while, rather than committing a large amount simply because the backtest curve looks appealing.
Next time you see any DeFAI product showcase an impressive backtest return, don't rush to be convinced by the number — spend a few minutes running these three checks: is there out-of-sample test data, can the core logic be explained simply, and has there been a sudden performance cliff since going live. The answers to these three questions tell you far more about whether a strategy deserves your trust than the backtest return figure alone.